Komori
Revision of earnings forecasts4516Nippon Shinyaku Co.,Ltd.Pharmaceuticals

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 2025 [IFRS] (Consolidated)

2025年3月期の通期業績予想を上方修正した。売上収益・営業利益・税引前利益は各30億円、親会社の所有者に帰属する当期利益は15億円引き上げた。

Worth reading
64In focus
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
3000
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2025 · Full yearPrevious forecast published 2024年11月13日
Net Sales157,000→160,000million
+1.9%
Operating profit33,000→36,000million
+9.1%
Profit attributable to owners of the parent30,000→31,500million
+5.0%
Net income per share445.24→467.51yen and sen
+5.0%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

「ウプトラビ」の海外売上に伴うロイヤリティ収入および「ビルテプソ」「ビキセオス」等の新製品群の売上収益が予想を上回ったこと。

Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥157,000 million → ¥160,000 million(+1.9%)
Operating profit¥33,000 million → ¥36,000 million(+9.1%)
Profit attributable to owners of the parent¥30,000 million → ¥31,500 million(+5.0%)
Net income per share445.24 yen and sen → 467.51 yen and sen
Fiscal Period CoveredFiscal year ending March 2025
Period CoveredFull year
Publication date of previous forecast2024年11月13日
Reason for the revision「ウプトラビ」の海外売上に伴うロイヤリティ収入および「ビルテプソ」「ビキセオス」等の新製品群の売上収益が予想を上回ったこと。
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Items this document does not state (3)
Ordinary incomePrevious-period resultsDetails and amount of extraordinary loss

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

第3四半期累計期間の実績を踏まえ、「ウプトラビ」の海外売上に伴うロイヤリティ収入や、「ビルテプソ」「ビキセオス」など新製品群の売上収益が予想を上回ったため。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 2025 [IFRS] (Consolidated) | Nippon Shinyaku Co.,Ltd. (4516) timely disclosure | Komori